CAS 1128096-91-2

Formule : C28H26N8O

InChI : InChI=1S/C28H26N8O/c1-20-5-6-22(18-30-20)27-31-19-36(34-27)24-9-7-23(8-10-24)32-28-29-12-11-26(33-28)21-3-2-4-25(17-21)35-13-15-37-16-14-35/h2-12,17-19H,13-16H2,1H3,(H,29,32,33)

Code InChI : QDMXVKKPYBGIAS-UHFFFAOYSA-N

SMILES : CC1=NC=C(C=C1)C2=NN(C=N2)C3=CC=C(C=C3)NC4=NC=CC(=N4)C5=CC(=CC=C5)N6CCOCC6

Sr-3306

CAS : 1128096-91-2

Sr-3306

Formule : C₂₈H₂₆N₈O

Masse moléculaire : 490.55903

Ref: 54-BISN0314

SR-3306

CAS : 1128096-91-2

SR-3306

Formule : C₂₈H₂₆N₈O

Degré de pureté : 99.5%

Masse moléculaire : 490.56

Ref: 54-BUP12804

SR-3306

CAS : 1128096-91-2

Formule : C₂₈H₂₆N₈O

Masse moléculaire : 490.559

Ref: IN-DA008TN6

SR-3306

CAS : 1128096-91-2

SR-3306 is a brain-penetrant and selective pan-JNK (JNK1/2/3) inhibitor with IC50 values ​​of 67 nM, 283 nM, 159 nM.Cost-effective and quality-assured.

Formule : C₂₈H₂₆N₈O

Degré de pureté : 99.38% - 99.71%

Couleur et forme : Solid

Masse moléculaire : 490.559

Ref: TM-T16927

Sr-3306

CAS : 1128096-91-2

Sr-3306 is a nonsteroidal anti-inflammatory drug (NSAID) that is the active form of the prodrug sulfasalazine. It inhibits prostaglandin synthesis by blocking cyclooxygenase (COX) activity and preventing the conversion of arachidonic acid to prostaglandins, which are important mediators of inflammation. Sr-3306 also inhibits COX-2 expression through a variety of mechanisms, including inhibition of NF-κB signaling pathways and activation of peroxisome proliferator-activated receptor gamma (PPARγ). It has been shown to inhibit cell growth in cancer cells and has neuroprotective effects against dopamine toxicity in animal models. In addition, it has been shown to inhibit epidermal growth factor (EGF), which causes inflammation and tumorigenesis, as well as inhibitory effects on the development of acute ischemic stroke.

Formule : C₂₈H₂₆N₈O

Degré de pureté : Min. 95%

Masse moléculaire : 490.56 g/mol

Ref: 3D-DVB09691